Drug Trial Radar · NCT03947385
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
Last checked: Nov 20, 2026Latest source record: Jun 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
336
Planned (sponsor's estimate)
Start
Jun 28, 2019
Primary completion
Jan 29, 2027
Study completion Jun 15, 2027
Sponsor
- Lead sponsor
- IDEAYA BiosciencesIndustry
- Sponsor type
- Industry
- First posted
- May 13, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1/2, multi-center, open-label basket study designed to evaluate the safety and anti-tumor activity of IDE196 in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) mutations or PRKC fusions, including metastatic uveal melanoma (MUM), cutaneous melanoma, colorectal cancer, and other solid tumors. Phase 1 (dose escalation - monotherapy) will assess safety, tolerability and pharmacokinetics of IDE196 via standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and anti-tumor activity will be assessed in the Phase 2 (dose expansion) part of the study. Phase 1 (dose escalation - binimetib combination) will assess safety, tolerability and pharmacokinetics of IDE196 and binimetinib via standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and anti-tumor activity will be assessed in the Phase 2 (dose expansion) part of the study. Phase 1 (dose escalation - crizotinib combination) will assess safety, tolerability and pharmacokinetics of IDE196 and crizotinib via standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and anti-tumor activity will be assessed in the Phase 2 (dose expansion) part of the study. Evaluation of safety and efficacy across multiple doses may be explored in the dose optimization part of the study. Crizotinib monotherapy with crossover to combination cohort may be assessed for safety and to show the contribution of each study drug to anti-tumor activity. As of Protocol Amendment 10, Phase 1, Phase 2 dose expansion in IDE196 monotherapy, and Phase 2 dose expansion of IDE196 in combination with binimetinib have been fully enrolled. There were no patients enrolled in the crizotinib monotherapy cohorts.
Conditions
- Metastatic Uveal Melanoma
- Cutaneous Melanoma
- Colorectal Cancer
- Other Solid Tumors
Interventions
IDE196Drug
IDE196 dosed orally, twice daily for each 28-day cycle
BinimetinibDrug
Binimetinib dosed orally, twice daily for each 28-day cycle
CrizotinibDrug
Crizotinib dosed orally, twice daily for each 28-day cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-limiting Toxicity (DLT)Time frame: 28 days following first dose of IDE196 as monotherapy, in combination with Binimetinib, or in combination with Crizotinib
- Incidence of Adverse EventsTime frame: Approx. 8 months
- Maximum Tolerated Dose (MTD)Time frame: 28 days following first dose of IDE196 as monotherapy, in combination with Binimetinib, or in combination with Crizotinib
- Recommended Phase 2 Dose (RP2D) as monotherapy, in combination with Binimetinib, or in combination with CrizotinibTime frame: Approx. 6 months
- Plasma Concentrations of IDE196 as monotherapy, in combination with Binimetinib, or in combination with CrizotinibTime frame: Approx. 6 months
- Plasma Concentrations of Crizotinib administered in combination with IDE196Time frame: Approx. 6 months
- Plasma Concentrations of Binimetinib administered in combination with IDE196Time frame: Approx. 6 months
- Overall Response Rate (ORR) of IDE196 monotherapy, in combination with Binimetinib, and in combination with Crizotinib in Dose Expansion cohorts by Investigator response assessmentTime frame: Approx. 8 months
- Duration of Response (DOR) of IDE196 monotherapy, in combination with Binimetinib, and in combination with Crizotinib in Dose Expansion cohorts by Investigator response assessmentTime frame: Approx. 8 months
Locations
15 sites in 3 countries. Site status is shown where the registry gives one.
UCLA Medical Center
Los Angeles, California · Recruiting
San Francisco Oncology Associates
San Francisco, California · Active not recruiting
SCRI - Denver
Denver, Colorado · Recruiting
University of Iowa
Iowa City, Iowa · Active not recruiting
Cancer Hematology Centers Western Michigan
Grand Rapids, Michigan · Active not recruiting
Columbia University Medical Center - Herbert Irving Pavilion
New York, New York · Active not recruiting
Duke University Medical Center
Durham, North Carolina · Recruiting
University of Cincinnati Cancer Center
Cincinnati, Ohio · Recruiting
The Cleveland Clinic Foundation
Cleveland, Ohio · Active not recruiting
Sidney Kimmel Cancer Center at Thomas Jefferson University
Philadelphia, Pennsylvania · Recruiting
The Sarah Cannon Research Institute/Tennessee Oncology
Nashville, Tennessee · Recruiting
The University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
Queensland
Woolloongabba, Australia · Active not recruiting
Westmead Hospital
Sydney, New South Wales, Australia · Active not recruiting
Princess Margaret Cancer Centre
Toronto, Ontario, Canada · Active not recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.